Popeo

Popeo Therapeutics is a pre-clinical stage biotechnology company focused on the development of novel small molecule inhibitors for the treatment of cancer and inflammatory diseases. The company's primary research efforts center on targeting the PI3K/AKT/mTOR signaling pathway, with a specific emphasis on the delta and gamma isoforms of phosphoinositide 3-kinase (PI3K). By developing selective inhibitors, Popeo Therapeutics aims to modulate immune responses and inhibit tumor growth while minimizing the off-target toxicities associated with pan-PI3K inhibition. The company is currently advancing its lead programs through early-stage discovery and pre-clinical validation.